CU24196B1 - Anticuerpos monoclonales frente a progastrina - Google Patents

Anticuerpos monoclonales frente a progastrina

Info

Publication number
CU24196B1
CU24196B1 CUP2012000060A CU20120060A CU24196B1 CU 24196 B1 CU24196 B1 CU 24196B1 CU P2012000060 A CUP2012000060 A CU P2012000060A CU 20120060 A CU20120060 A CU 20120060A CU 24196 B1 CU24196 B1 CU 24196B1
Authority
CU
Cuba
Prior art keywords
monoclonal antibodies
progastrin
methods
progastrine
antibodies against
Prior art date
Application number
CUP2012000060A
Other languages
English (en)
Spanish (es)
Other versions
CU20120060A7 (es
Inventor
Julie Pannequin
Laure Boudier
Dominique Joubert
Frédéric Hollande
Original Assignee
Servier Lab
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24196(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Servier Lab
Publication of CU20120060A7 publication Critical patent/CU20120060A7/es
Publication of CU24196B1 publication Critical patent/CU24196B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/57535—
    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CUP2012000060A 2009-10-16 2012-04-16 Anticuerpos monoclonales frente a progastrina CU24196B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Publications (2)

Publication Number Publication Date
CU20120060A7 CU20120060A7 (es) 2013-04-19
CU24196B1 true CU24196B1 (es) 2016-09-30

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2012000060A CU24196B1 (es) 2009-10-16 2012-04-16 Anticuerpos monoclonales frente a progastrina

Country Status (42)

Country Link
US (7) US9611320B2 (enExample)
EP (2) EP3421493B1 (enExample)
JP (3) JP5985987B2 (enExample)
KR (2) KR20120091221A (enExample)
CN (2) CN102791735B (enExample)
AP (1) AP2012006262A0 (enExample)
AR (1) AR078659A1 (enExample)
AU (1) AU2010306119A1 (enExample)
BR (1) BR112012008818B1 (enExample)
CA (1) CA2777691C (enExample)
CL (1) CL2012000914A1 (enExample)
CR (1) CR20120184A (enExample)
CU (1) CU24196B1 (enExample)
CY (1) CY1120913T1 (enExample)
DK (1) DK2488551T3 (enExample)
EA (2) EA029271B1 (enExample)
EC (1) ECSP12011796A (enExample)
ES (2) ES2690943T3 (enExample)
GE (1) GEP201706604B (enExample)
GT (1) GT201200114A (enExample)
HN (1) HN2012000708A (enExample)
HR (1) HRP20181645T1 (enExample)
IL (2) IL219019B (enExample)
IN (1) IN2012DN03348A (enExample)
LT (1) LT2488551T (enExample)
MA (1) MA33747B1 (enExample)
MX (1) MX351635B (enExample)
NI (1) NI201200054A (enExample)
NZ (2) NZ701709A (enExample)
PE (1) PE20121649A1 (enExample)
PH (1) PH12012500711B1 (enExample)
PL (2) PL3421493T3 (enExample)
PT (1) PT2488551T (enExample)
RS (1) RS57966B1 (enExample)
SG (1) SG10201704933PA (enExample)
SI (1) SI2488551T1 (enExample)
SM (1) SMT201800628T1 (enExample)
TN (1) TN2012000159A1 (enExample)
TW (1) TWI537002B (enExample)
UA (1) UA106771C2 (enExample)
WO (1) WO2011045080A2 (enExample)
ZA (1) ZA201202642B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
PL3421493T3 (pl) * 2009-10-16 2024-04-29 Progastrine Et Cancers S.À R.L. Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US20150071912A1 (en) * 2010-03-24 2015-03-12 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
SG187544A1 (en) * 2010-07-26 2013-03-28 Servier Lab Methods and compositions for liver cancer therapy
US8785603B2 (en) * 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
CN105517572B (zh) * 2013-07-05 2019-05-31 华盛顿大学商业中心 用于治疗癌症的中和可溶性mic的单克隆抗体
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
ES2843546T3 (es) * 2014-04-18 2021-07-19 The Research Foundation Of The State Univ Of New York Anticuerpos humanizados anti-antígeno-TF
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
WO2017048629A1 (en) * 2015-09-15 2017-03-23 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
PL3397964T3 (pl) * 2015-12-31 2022-02-07 Progastrine Et Cancers S.À R.L. Kompozycje i sposoby do wykrywania i leczenia raka jajnika
MA43550A (fr) * 2015-12-31 2018-11-07 Syncerus S A R L Compositions et procédés d'évaluation du risque d'apparition d'un cancer
ES2899360T3 (es) 2015-12-31 2022-03-11 Progastrine Et Cancers S A R L Composiciones y procedimientos para detectar y tratar cáncer gástrico
AU2018246368B2 (en) * 2017-03-30 2023-02-09 Ecs-Progastrin Sa Compositions and methods for detecting lung cancer
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
PL3720879T3 (pl) * 2017-12-05 2022-09-12 Progastrine Et Cancers S.À R.L. Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu
CN112004560A (zh) 2017-12-08 2020-11-27 Ecs生物识别系统有限公司 癌症诊断中的放射性标记的前胃液素
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
KR102699073B1 (ko) * 2018-02-27 2024-08-26 이씨에스-프로가스트린 에스에이 면역치료요법용 생체표지자로서 프로가스트린
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
CN112062846A (zh) * 2020-04-27 2020-12-11 杭州博茵生物技术有限公司 一种g-17单克隆抗体及其应用
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN115724949A (zh) * 2022-12-12 2023-03-03 郑州伊美诺生物技术有限公司 一种鼠源lgG单克隆抗体及其制备方法、应用
CN116143920A (zh) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 胃泌素17的单克隆抗体及其细胞株的制备方法和应用
EP4509528A1 (en) * 2023-08-16 2025-02-19 Barrelman Biosciences LLC Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN117567611B (zh) * 2023-11-22 2024-05-14 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1794586B1 (en) * 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
ES2727306T3 (es) * 2006-05-22 2019-10-15 Inst Nat Sante Rech Med Inhibidores de progastrina en el tratamiento del cáncer de colon
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
PL3421493T3 (pl) * 2009-10-16 2024-04-29 Progastrine Et Cancers S.À R.L. Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
US20150071912A1 (en) * 2010-03-24 2015-03-12 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
SG187544A1 (en) * 2010-07-26 2013-03-28 Servier Lab Methods and compositions for liver cancer therapy

Also Published As

Publication number Publication date
CY1120913T1 (el) 2019-12-11
US20170174761A1 (en) 2017-06-22
CA2777691C (en) 2018-02-27
PH12012500711B1 (en) 2019-04-24
PE20121649A1 (es) 2012-12-08
US9611320B2 (en) 2017-04-04
JP2013507138A (ja) 2013-03-04
TN2012000159A1 (en) 2013-12-12
CA2777691A1 (en) 2011-04-21
ES2973217T3 (es) 2024-06-19
US20170306011A1 (en) 2017-10-26
IL219019B (en) 2019-05-30
GT201200114A (es) 2014-08-11
KR101640520B1 (ko) 2016-07-19
CR20120184A (es) 2012-08-20
AU2010306119A1 (en) 2012-05-03
US11299542B2 (en) 2022-04-12
SI2488551T1 (sl) 2019-01-31
JP2017212992A (ja) 2017-12-07
IN2012DN03348A (enExample) 2015-10-23
KR20120091221A (ko) 2012-08-17
LT2488551T (lt) 2018-10-25
NZ701709A (en) 2016-06-24
MX351635B (es) 2017-10-23
PH12012500711A1 (en) 2012-11-12
TWI537002B (zh) 2016-06-11
BR112012008818B1 (pt) 2021-10-19
DK2488551T3 (en) 2018-10-08
US20220195035A1 (en) 2022-06-23
CN102791735A (zh) 2012-11-21
IL254004A0 (en) 2017-10-31
EP2488551A2 (en) 2012-08-22
IL219019A0 (en) 2012-06-28
US20180022802A1 (en) 2018-01-25
RS57966B1 (sr) 2019-01-31
GEP201706604B (en) 2017-01-25
WO2011045080A3 (en) 2011-07-07
TW201119675A (en) 2011-06-16
CU20120060A7 (es) 2013-04-19
EA029271B1 (ru) 2018-03-30
US20110117086A1 (en) 2011-05-19
JP2015145380A (ja) 2015-08-13
PT2488551T (pt) 2018-10-31
CL2012000914A1 (es) 2012-09-14
US10385126B2 (en) 2019-08-20
MX2012004400A (es) 2012-06-27
JP5985987B2 (ja) 2016-09-06
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
JP6272793B2 (ja) 2018-01-31
EP3421493B1 (en) 2024-01-17
EP3421493C0 (en) 2024-01-17
HN2012000708A (es) 2015-06-22
ZA201202642B (en) 2013-06-26
IL254004B2 (en) 2023-06-01
ECSP12011796A (es) 2012-06-29
HRP20181645T1 (hr) 2018-12-14
US10385125B2 (en) 2019-08-20
WO2011045080A2 (en) 2011-04-21
EP3421493A1 (en) 2019-01-02
SMT201800628T1 (it) 2019-01-11
PL3421493T3 (pl) 2024-04-29
HK1178183A1 (zh) 2013-09-06
ES2690943T3 (es) 2018-11-23
NZ599971A (en) 2014-12-24
SG10201704933PA (en) 2017-07-28
EA201200597A1 (ru) 2012-12-28
AP2012006262A0 (en) 2012-06-30
MA33747B1 (fr) 2012-11-01
US10385124B2 (en) 2019-08-20
US20170306012A1 (en) 2017-10-26
EP2488551B1 (en) 2018-07-25
US20200002413A1 (en) 2020-01-02
PL2488551T3 (pl) 2019-01-31
KR20150082672A (ko) 2015-07-15
UA106771C2 (uk) 2014-10-10
NI201200054A (es) 2012-08-20
BR112012008818A2 (en) 2018-05-22
CN104628857A (zh) 2015-05-20
EA201791876A1 (ru) 2018-01-31
US10377821B2 (en) 2019-08-13

Similar Documents

Publication Publication Date Title
CU20120060A7 (es) Anticuerpos monoclonales frente a progastrina
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
MX362720B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
GT201200318A (es) Anticuerpos hacia gdf8 humano
BR112015003757A2 (pt) anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
CR20120036A (es) Terapia de combinación de un anticuerpo cd20 afucosilado y bendamustina
MX352373B (es) Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
EA201270315A1 (ru) Новые формы полициклического соединения
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
CL2012000387A1 (es) Método para tratar a un paciente diagnosticado con cáncer de mama previamente tratado metastásico que comprende la combinación de una quimioterapia con la administración de un anticuerpo anti-vegf; y kit utilizado.
AR081565A1 (es) Metodos para tratar cancer de ovario sensible a platino recurrente con 4-yodo-3-nitrobenzamida en combinacion con un anti-metabolito y un compuesto de platino
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.
BR112014028507A2 (pt) anticorpos cd33 e uso dos mesmos para tratar câncer
UA47985U (ru) Способ прогнозирования выживаемости больных раком яичника, которые не проходили неадьювантную полихимиотерапию после оперативного вмешательства

Legal Events

Date Code Title Description
FG Grant of patent